Human Immunodeficiency Virus‐Associated Thrombotic Microangiopathies: Clinical Characteristics and Outcome According to ADAMTS13 Activity

Human immunodeficiency virus (HIV) infection is a risk factor for thrombotic microangiopathy (TMA). We sought whether a severe deficiency in ADAMTS13, the enzyme specifically involved in the cleavage of von Willebrand factor, was associated with specific presenting features and outcome in HIV‐associated TMA. In this prospective, multicentre, case–control study, 29 patients of 236 in the French Network on TMA had an HIV‐associated TMA. Seventeen patients with severe ADAMTS13 deficiency (ADAMTS13